Abstract:Background: Cluster of Differentiation 93 (CD93) plays an important role in angiogenesis and is considered an important target for inhibiting tumor angiogenesis, but there are currently no therapeutic antibodies against CD93 in the clinic. Thus, we describe the screening of novel nanobodies (Nbs) targeting human CD93 from a phage library of shark-derived Nbs. Methods: Screening and enrichment of phage libraries by enzyme-linked immunosorbent assay (ELISA). Anti-CD93 Nbs were purified by expression in E. coli . The binding affinity of anti-CD93 Nbs NC81/NC89 for CD93 was examined by flow cytometry (FC) and ELISA. The thermal stability of NC81/NC89 was examined by ELISA and CD spectroscopy. Afterward, the anti-angiogenic ability of NC81/NC89 was examined by MTT, wound healing assay, and tube formation assay. The expression level of VE-cadherin (VE-Ca) and CD93 was detected by Western Blot (WB). The binding sites and binding forms of NC81/NC89 to CD93 were analyzed by molecular docking. Results: The anti-CD93 Nbs were screened in a phage library, expressed in E. coli , and purified to >95% purity. The results of FC and ELISA showed that NC81/NC89 have binding ability to human umbilical vein endothelial cells (HUVECs). The results of ELISA and CD spectroscopy showed that NC81/NC89 retained the ability to bind CD93 at 80°C and that the secondary structure remained stable. In vitro , the results showed that NC81 and NC89 significantly inhibited the proliferation and migration of human umbilical vein endothelial cells (HUVECs) as well as tube formation on Matrigel. Western Blot showed that NC81 and NC89 also inhibited the expression of VE-Ca thereby increasing vascular permeability. It was found during molecular docking that the CDR regions of NC81 and NC89 could be attached to CD93 by strong hydrogen bonds and salt bridges, and the binding sites were different. Conclusion: We have successfully isolated NC81 and NC89, which bind CD93, and both Nbs significantly inhibit angiogenesis and increase vascular permeability. These results suggest that NC81 and NC89 have potential clinical applications in angiogenesis-related therapies.

In situ construction of ligand nano-network to integrin αvβ3 for angiogenesis inhibition

Construction of pcDNA3-Endo eukaryon expression plasmid and angiogenesis inhibition in vitro

Perfusable Vessel-on-a-Chip for Antiangiogenic Drug Screening with Coaxial Bioprinting

Supramolecular nanofibers with superior anti-angiogenesis and antitumor properties by enzyme-instructed self-assembly (EISA)

Molecular Imaging of Tumor Angiogenesis Using Rgd-Labeled Iron Oxide Nanoparticles

An antibody-like peptidic network for anti-angiogenesis

A self-assembling peptide targeting VEGF receptors to inhibit angiogenesis

Screening and construction of nanobodies against human CD93 using phage libraries and study of their antiangiogenic effects

Sigma Receptor-Mediated Targeted Delivery of Anti-Angiogenic Multifunctional Nanodrugs for Combination Tumor Therapy

In Vitro Evaluation of Panax Notoginseng Rg1 Released from Collagen/chitosan-Gelatin Microsphere Scaffolds for Angiogenesis

Synthesis and Antitumor Application of Antiangiogenetic Gold Nanoclusters

FP3: a Novel VEGF Blocker with Antiangiogenic Effects in Vitro and Antitumour Effects in Vivo

Integrin αvβ3-targeted cancer therapy

Bioinspired Self-assembling Peptide Hydrogel with Proteoglycan-assisted Growth Factor Delivery for Therapeutic Angiogenesis

A Lipopeptide-Based Αvβ3 Integrin-Targeted Ultrasound Contrast Agent for Molecular Imaging of Tumor Angiogenesis

Angio-3, a 10-Residue Peptide Derived from Human Plasminogen Kringle 3, Suppresses Tumor Growth in Mice Via Impeding Both Angiogenesis and Vascular Permeability

Integrin Alpha(v)beta(3)-Targeted Cancer Therapy.

Molecularly Imprinted Nanomedicine for Anti-angiogenic Cancer Therapy Via Blocking Vascular Endothelial Growth Factor Signaling.

In Vivo Studies on Angiogenic Activity of Two Designer Self-Assembling Peptide Scaffold Hydrogels in the Chicken Embryo Chorioallantoic Membrane

Inhibition of Lymphangiogenesis of Endothelial Progenitor Cells with Vegfr-3 Sirna Delivered with Pei-Alginate Nanoparticles

A Hybrid Protein Comprising ATF Domain of Pro‐uk and VAS, an Angiogenesis Inhibitor, is a Potent Candidate for Targeted Cancer Therapy